Acute presentation of immunotherapy-related diabetes mellitus without ketoacidosis, low C-peptide or elevated HbA1c

SUMMARY: The rapid rise in the use of immune checkpoint inhibitors as systemic cancer therapy has seen the emergence of immunotherapy-induced diabetes, a severe irreversible immunotherapy-related adverse event. Affected patients typically present with diabetic ketoacidosis (DKA) and low C-peptide co...

Descripción completa

Detalles Bibliográficos
Autores principales: Phang, Cun An, Kumar, Shejil, Rohl, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2022
Materias:
Unique/Unexpected Symptoms or Presentations of a Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716361/
https://www.ncbi.nlm.nih.gov/pubmed/36448841
http://dx.doi.org/10.1530/EDM-22-0291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716361/
https://www.ncbi.nlm.nih.gov/pubmed/36448841
http://dx.doi.org/10.1530/EDM-22-0291

Ejemplares similares